Synthesis and Pharmacology of Ester Modified (+/-)-threo-Methylphenidate Analogs

TL;DR

This study synthesized eleven ester-modified (+/-)-threo-methylphenidate analogs to evaluate their potency against dopamine and serotonin transporters, aiming to develop potential treatments for cocaine abuse.

Contribution

It introduces novel ester-modified TMP derivatives and assesses their transporter binding affinities, providing insights into structure-activity relationships relevant to drug development.

Findings

Potencies ranged from 27 nM to 7,000 nM against dopamine transporter.

Most compounds were less potent against serotonin transporter than dopamine transporter.

Certain structural features influenced binding affinity and selectivity.

Abstract

As part of a program to develop compounds with potential to treat cocaine abuse, eleven (+/-)-threo-methylphenidate (TMP; Ritalin) derivatives were synthesized and tested in rat striatal tissue preparations for inhibitory potency against [3H]WIN 35,428 binding (WIN) to the dopamine (DA) transporter, [3H]citalopram binding (CIT) to the serotonin transporter, and [3H]DA uptake. The ester function was replaced by other functional groups in all of the compounds; some also contained substituents on the phenyl ring and/or the piperidine nitrogen. Potencies against WIN, measured as IC50, ranged from 27 nM to 7,000 nM, compared to an IC50 of 83 nM for TMP itself. Potency against [3H]DA uptake was approximately two-fold less than that against WIN, but generally exhibited the same rank order. With one exception, the compounds were significantly less potent against CIT than WIN. The one exception, which has a rigid planar conformation at the altered ester position, is unique in that it also is much less potent against [3H]DA uptake relative to WIN, compared to the other derivatives. The three compounds with dichloro groups on the phenyl ring did not exhibit positive cooperativity, as has been observed with several previously synthesized halogenated TMP derivatives. Taken together, these compounds should help to further our understanding of the stimulant binding sites on both the dopamine and serotonin transporters.